Currently licenced direct oral anticoagulants selectively target thrombin (eg, dabigatran) or
coagulation factor Xa (eg, apixaban, betrixaban, edoxaban, and rivaroxaban). Designed to …

Deep venous thrombosis (DVT) is part of a spectrum of venous thromboembolic disorders
that includes superficial thrombophlebitis and pulmonary embolism. 1 DVT may be defined …

The non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which
inhibits thrombin, and apixaban, betrixaban, edoxaban, and rivaroxaban, which inhibit …

Abstract Background Trial of Rivaroxaban in AntiPhospholipid Syndrome was a prospective
randomized, open‐label, noninferiority study conducted in 14 centers in Italy. Rivaroxaban …

Although anticoagulants have been in use for more than 80 years, heparin and vitamin K
antagonists were the sole available options until recently. Although these agents …

Venous thromboembolism (VTE), the third most frequent acute cardiovascular syndrome, is
associated with a considerable disease burden which continues to grow along with the …

FXI (factor XI) and FXII (factor XII) have emerged as targets for new anticoagulants that have
the potential to be both more efficacious and safer than the currently available direct oral …

Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and
pulmonary embolism (PE), is the third most common cause of vascular death after heart …

Thrombosis is a leading cause of death and disability worldwide, and anticoagulants are the
mainstay of its prevention and treatment. Starting with unfractionated heparin (UFH) and …

Platelet-neutrophil interactions are important for innate immunity, but also contribute to the
pathogenesis of deep vein thrombosis, myocardial infarction and stroke. Here we report that …